Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNX-5422 in TP53 Null Cancers
NCT02612285Phase 2Terminated
- Sponsor
- Esanex, Inc.
- Start
- Mar 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of snx-5422 in solid tumor, hematological malignancies, sponsored by Esanex, Inc.. Started Mar 2016; status: terminated.
02
Drugs
snx-5422
03
Conditions
solid tumorhematological malignancies
Beyond the preview
Go deeper on NCT02612285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612285.